Results from the open-label extension of a phase 3 trial showed that treatment with ravulizumab sustained clinical benefits for up to 4 years in patients with generalized myasthenia gravis.:
Source: Neurology Read More
Final CHAMPION MG Trial Data Show Sustained Benefit, Safety of Ravulizumab in Myasthenia Gravis
Related Posts
<![CDATA[FDA AdComm Votes Against Recommending
Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in
AD, Salanersen’s FDA Breakthrough Designation
Meaning]]>
<![CDATA[FDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen’s FDA Breakthrough Designation Meaning]]>
